share_log

Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN

ヴェラ・セラピューティクスは、IgANにおけるアタシセプトの大規模第3相ORIGIN 3トライアルの主要エンドポイントの募集を完了しました。

Benzinga ·  09/12 08:01
  • On track to announce topline results from ORIGIN 3 trial in Q2 2025
  • Expect to present 96-week data from ORIGIN Phase 2b clinical trial of atacicept in IgAN in Q4 2024

BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed enrollment ahead of schedule for the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial of atacicept in patients with IgAN. The enrollment of 200 participants in this initial cohort of the trial will provide data for the 36-week UPCR primary efficacy endpoint, supporting the subsequent submission for regulatory approval.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする